The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) trial was a randomized, multicenter, double-blinded, placebo-controlled trial that set out to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes in patients with HFpEF11. The gene discussed is SLC5A2; the disease is heart failure.